Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Seth Cahn

Neurology Greensburg, IN Medical Doctor

NPI 1023147261 CMS profile 227255

720 N Lincoln St, Greensburg, IN 47240

Open in the dashboard

General payments

$1,336

58 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Seth Cahn of Greensburg, IN is reported in the CMS Open Payments database as having received $1,336 across 58 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 49th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $54 3
2023 General $224 12
2022 General $635 21
2021 General $295 18
2020 General $89 2
2019 General $39 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Seth Cahn
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Seth Cahn were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Seth Cahn Neurology median Middle half National median
2019 $39 $474 $118–$2,177 $163
2020 $89 $367 $82–$2,309 $114
2021 $295 $438 $104–$2,547 $132
2022 $635 $442 $103–$2,388 $149
2023 $224 $464 $119–$2,312 $160
2024 $54 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. LivaNova USA, Inc. $339 3 payments
  2. AbbVie, Inc. $266 15 payments
  3. Biogen, Inc. $177 6 payments
  4. Lilly USA, LLC $173 11 payments
  5. Acorda Therapeutics, Inc $61 3 payments
  6. Teva Pharmaceuticals USA, Inc. $47 3 payments
  7. Janssen Pharmaceuticals, Inc $45 3 payments
  8. Biohaven Pharmaceuticals, Inc. $45 3 payments
  9. Argenx US, Inc. $37 2 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $27 2 payments
  11. Other $121 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,275 55 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $61 3 payments
Products named General payments · program years 2019–2024
  1. VNS Therapy $320 2 payments
  2. EMGALITY $173 11 payments
  3. UBRELVY $163 10 payments
  4. QULIPTA $103 5 payments
  5. ADUHELM $75 3 payments
  6. NURTEC ODT $72 5 payments
  7. INBRIJA $61 3 payments
  8. Ponvory $45 3 payments
  9. VYVGART $37 2 payments
  10. REYVOW $29 2 payments
  11. Other $217 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

480

Median for Neurology: 833

Drug cost

$116,197

Median for Neurology: $202,670

Branded share of claims

16.2%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Austedo Deutetrabenazine Brand 18 $105,366
Dalfampridine Er Dalfampridine Brand 12 $2,583
Levetiracetam Generic 35 $1,315
Ropinirole Hcl Generic 58 $1,268
Lamotrigine Generic 55 $1,252
Oxcarbazepine Generic 12 $743
Gabapentin Generic 57 $695
Clonazepam Generic 35 $513
Rizatriptan Rizatriptan Benzoate Brand 19 $486
Baclofen Generic 27 $460

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AJOVY
  • Teva Pharmaceuticals USA, Inc. $19
$19 — —
VUMERITY
  • Biogen, Inc. $8
$8 — —
AVONEX
  • Biogen, Inc. $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

58 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record